Search

Integrated Solutions Specialised Platform to Address Growing Demand of Pharma Companies

| Editor: Ahlam Rais

The Xcelerate Integrated Solutions platform by Piramal Pharma Solutions stands out for its speed, flexibility, and versatility. The solution is also backed by a track record of over 70 recent programmes, with investments in systems and capabilities, for a seamless customer experience.

Related Companies

The platform will serve the increasing demand from pharmaceutical firms for preferred partnerships with organisations that can provide world-class solutions across a range of verticals.
The platform will serve the increasing demand from pharmaceutical firms for preferred partnerships with organisations that can provide world-class solutions across a range of verticals.
(Source: Deposit Photos )

Piramal Pharma Solutions (PPS) has recently announced the launch of its Xcelerate Integrated Solutions platform to address a rapidly growing market need. This platform will serve the increasing demand from pharmaceutical firms, both large and small, for preferred partnerships with organisations that can provide world-class solutions across a range of verticals - drug discovery, drug substance, drug product, and clinical trial services. Rationalisation, restructuring initiatives, and consolidation among customers, combined with an increasing interest in virtualisation have led to externalisation of clinical programme development as a preferred option. Recently, as Contract Manufacturing Organisations have developed scale and expertise across multiple verticals, customers have begun to consider 'programme based outsourcing' for better efficiency on time, costs, and management, states the company.

Xcelerate Integrated Solutions stands out for its flexibility and versatility. For example, the extensive network of PPS sites across the globe allows customers to launch local - irrespective of whether it is North America, Europe, or Asia. According to the firm, the Xcelerate platform provides integrated solutions for orphan diseases, niche therapies, and fast track medicines, where the volume requirements are small, while also having the capacity and track record to address large volume needs of metabolic diseases and neuroscience therapies. The distinct footprint of PPS, with around half its sites in the East and the other half in the West, allows customers to manufacture the final API or Drug product out of the West, while back integrating into starting materials and intermediates out of its sites in the East.

PPS offers platform solutions from Discovery through Commercialisation with 12 R&D and manufacturing locations across North America, Europe, and Asia. Over the past two years, PPS has integrated these services together to offer a seamless solution to customers. In parallel, PPS has also addressed gaps in its integrated offerings through both, acquisitions and internal investments, adds the company. For example, in oncology therapeutics, where there is significant customer interest, Piramal now offers a unique platform that includes high potency API, fill-finish, and Antibody Drug Conjugation (ADC) solutions. The integrated capabilities are augmented by customised IT systems that allow for real time access on programme progress.

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45646658)